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Intravitreal Injection of Ciliary Neurotrophic Factor (CNTF) Causes Peripheral
Remodeling and Does Not Prevent Photoreceptor Loss in Canine RPGR Mutant
Retina
Abstract
Ciliary neurotrophic factor (CNTF) rescues photoreceptors in several animal models of retinal
degeneration and is currently being evaluated as a potential treatment for retinitis pigmentosa in humans.
This study was conducted to test whether CNTF prevents photoreceptor cell loss in XLPRA2, an early
onset canine model of X-linked retinitis pigmentosa caused by a frameshift mutation in RPGR exon
ORF15. Four different treatment regimens of CNTF were tested in XLPRA2 dogs. Under anesthesia, the
animals received at different ages an intravitreal injection of 12 μg of CNTF in the left eye. The right eye
served as a control and was injected with a similar volume of phosphate buffered saline (PBS). Ocular
examinations were performed regularly during the treatment periods. At termination, the dogs were
euthanatized, eyes collected and the retinas were processed for embedding in optimal cutting
temperature (OCT) medium. The outer nuclear layer (ONL) thickness was evaluated on H&E sections and
values in both CNTF- and PBS-treated eyes were compared. Morphologic alterations in the peripheral
retina were characterized by immunohistochemistry using cell-specific markers. Cell proliferation in the
retinas was examined on semi-thin plastic sections, and by BrdU pulse-labeling and Ki67
immunohistochemistry on cryosections. All CNTF-treated eyes showed early clinical signs of corneal
epitheliopathy, subcapsular cataracts and uveitis. No statistically significant difference in ONL thickness
was seen between the CNTF- and PBS-injected eyes. Prominent retinal remodeling that consisted in an
abnormal increase in the number of rods, and in misplacement of some rods, cones, bipolar and Müller
cells, was observed in the peripheral retina of CNTF-treated eyes. This was only seen when CNTF was in
injected before the age at which the canine retina reaches full maturation. In XLPRA2 dogs, intravitreal
injections of CNTF failed to prevent photoreceptors from undergoing cell death in the central and midperipheral retina. CNTF also caused ocular side-effects and morphologic alterations in the periphery that
were consistent with cell dedifferentiation and proliferation. Our findings suggest that some inherited
forms of retinal degeneration may not respond to CNTF's neuroprotective effects.
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Intravitreal injection of ciliary neurotrophic factor (CNTF) causes
peripheral remodeling and does not prevent photoreceptor loss in
canine RPGR mutant retina
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Abstract
Ciliary neurotrophic factor (CNTF) rescues photoreceptors in several animal models of retinal
degeneration and is currently being evaluated as a potential treatment for retinitis pigmentosa in
humans. This study was conducted to test whether CNTF prevents photoreceptor cell loss in
XLPRA2, an early onset canine model of X-linked retinitis pigmentosa caused by a frameshift
mutation in RPGR exon ORF15.
Four different treatment regimens of CNTF were tested in XLPRA2 dogs. Under anesthesia, the
animals received at different ages an intravitreal injection of 12 μg of CNTF in the left eye. The right
eye served as a control and was injected with a similar volume of phosphate buffered saline (PBS).
Ocular examinations were performed regularly during the treatment periods. At termination, the dogs
were euthanatized, eyes collected and the retinas were processed for embedding in optimal cutting
temperature (OCT) medium. The outer nuclear layer (ONL) thickness was evaluated on H&E
sections and values in both CNTF- and PBS-treated eyes were compared. Morphologic alterations
in the peripheral retina were characterized by immunohistochemistry using cell-specific markers.
Cell proliferation in the retinas was examined on semi-thin plastic sections, and by BrdU pulselabeling and Ki67 immunohistochemistry on cryosections.
All CNTF-treated eyes showed early clinical signs of corneal epitheliopathy, subcapsular cataracts
and uveitis. No statistically significant difference in ONL thickness was seen between the CNTFand PBS-injected eyes. Prominent retinal remodeling that consisted in an abnormal increase in the
number of rods, and in misplacement of some rods, cones, bipolar and Müller cells, was observed in
the peripheral retina of CNTF-treated eyes. This was only seen when CNTF was in injected before
the age at which the canine retina reaches full maturation.
In XLPRA2 dogs, intravitreal injections of CNTF failed to prevent photoreceptors from undergoing
cell death in the central and mid-peripheral retina. CNTF also caused ocular side-effects and
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morphologic alterations in the periphery that were consistent with cell dedifferentiation and
proliferation. Our findings suggest that some inherited forms of retinal degeneration may not respond
to CNTF’s neuroprotective effects.

Keywords
neuroprotection; ciliary neurotrophic factor; retina; photoreceptors; RPGR; X-linked retinitis
pigmentosa; remodeling; dog

INTRODUCTION
Retinitis pigmentosa (RP) is a genetically heterogeneous group of diseases that constitutes one
of the leading causes of blindness worldwide, with an incidence of approximately 1: 4,000
(Boughman et al., 1980; Puech et al., 1991). Despite the identification over the past 20 years
of more than 50 genes responsible for RP (http://www.sph.uth.tmc.edu/Retnet/), currently there
is no treatment available that can either prevent, or slow-down the course of photoreceptor cell
death. A promising therapeutic approach, for which proof of principle has been demonstrated
in various animal models, is the use of corrective gene therapy (Acland et al., 2001; Pang et
al., 2006). Yet, such a strategy requires the identification of the mutated gene, and is therefore
aimed at targeting diseases in a gene-specific manner.
An approach that could potentially bypass the inherent limitation of gene-based therapy is the
use of neuroprotective agents that can rescue photoreceptors regardless of the genetic and/or
environmental causes of the retinal degeneration. Over the past 15 years, numerous survival
factors have been tested in a variety of animal models of RP [e.g. see: (LaVail et al., 1992;
Cayouette et al., 1999; Frasson et al., 1999)]. Among these agents, ciliary neurotrophic factor
(CNTF) has been shown to rescue photoreceptors in several rodent and large animal models
[for review see: (Beltran, 2006)]. Because of the inability for CNTF to cross the blood-retina
barrier following systemic administration, the necessity for sustained bioavailablity of the
agent in the eye, and the ocular side-effects associated with bolus intravitreal injection, a longterm intraocular delivery system has been developed (Thanos et al., 2004). This encapsulated
cell-based technology (ECT) allows for the continuous release of small quantities of CNTF
into the vitreous, and was evaluated in experimental animal models (Tao et al., 2002; Bush et
al., 2004), and more recently in Phase I clinical trial in humans (Sieving et al., 2006).
Previous work has shown that CNTF delivered through intravitreal injections (Pearce-Kelling,
unpublished study), or by means of an ECT device (Tao et al., 2002), rescues photoreceptors
in the rcd1 dog, an early and rapidly progressing large animal model of RP caused by a stop
mutation in PDE6B. The purpose of the present study was to determine whether intravitreal
injections of CNTF could provide a similar neuroprotective effect in XLPRA2, an early onset
model of X-linked RP caused by a frameshift mutation in RPGR exon ORF15 (Zhang et al.,
2002; Ferreira, 2005; Khanna et al., 2005). Recently, we reported the morphologic retinal
changes, and the kinetics of photoreceptor cell death, that occur during the course of this disease
(Beltran et al., 2006). Death of rods occurs in a biphasic manner, beginning as early as 4 weeks
of age, and reaching a peak at 6–7 weeks. Following this initial burst, the rate of cell death is
considerably slowed down, yet persists at an approximately constant rate for at least 9 months.
Based on these findings, the initial phase of cell death was selected as a time-window to evaluate
the neuroprotective effect of CNTF. Results show that intravitreal injections of CNTF at the
onset and/or peak of cell death do not prevent cell loss in the central and midperipheral XLPRA2
retina, but cause prominent remodeling in the periphery.
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METHODS
Expression and purification of recombinant CNTF protein
The open reading frame of human CNTF cDNA was PCR-cloned into the pQE30 expression
vector (Qiagen, Valencia, CA), and fused to a 6x His tag at the amino-terminus to generate
plasmid pQE-CNTF. Recombinant human CNTF protein was expressed in E. coli (XL-blue,
Stratagene, La Jolla, CA), and purified by immobilized-metal affinity chromatography on NiNTA Agarose columns (Qiagen) under native conditions. Eluted protein was buffer-exchanged
to phosphate buffered saline (PBS), and the protein concentration determined by the BCA
protein assay (Pierce, Rockford, IL). The CNTF solution was then diluted with PBS to a
concentration of 0.4 μg/μl, sterile filtered (Acrodisc Syringe filter 0.2 μm, Pall Corporation,
Ann Harbor, MI), and aliquots of 30 μl (12 μg) were stored at −80°C.
Animals
A total of 16 affected XLPRA2, 3 affected rcd1, and 1 non-mutant dog was used for this study.
All animals were bred and housed at the Retinal Disease Studies Facility (RDSF, University
of Pennsylvania, New Bolton Center, Kennett Square, PA). Their genotype was determined
either from the known status of their progenitors, or from genetic testing for the disease-causing
mutation (Ray et al., 1994; Zhang et al., 2002). All animals underwent an initial ocular
examination that confirmed the absence of clinically evident abnormalities.
Twelve XLPRA2 dogs were initially used in this study, and the animals were allocated to one
of the following treatment groups:
• Treatment Group #1 (n = 3): one single injection of CNTF at 4 weeks of age (see
below), termination at 8 weeks of age (Inj. 4 wk; Ter. 8 wk).
•
•
•

Treatment Group #2 (n = 3): injection of CNTF at 4 and 8 weeks of age, termination
at 12 weeks of age (Inj. 4 & 8 wk; Ter. 12 wk).
Treatment Group #3 (n = 3): injection of CNTF at 7 and 10 weeks of age, termination
at 14 weeks of age (Inj. 7 & 10 wk; Ter. 14 wk).
Treatment Group #4 (n = 3): one single injection of CNTF at 12 weeks, termination
at 15.6 weeks of age (Inj. 12 wk; Ter. 15.6 wk).

The primary aim of this study was to determine whether intravitreal bolus injections of CNTF
could arrest the course of photoreceptor cell death during the very early phase of the disease
[ie: when a rapid decline in ONL thickness and a burst of photoreceptor cell death occur
(Beltran et al., 2006)]. This was the basis for selecting the time of injection and termination of
treatment Groups #1, #2 and #3. We included as positive controls for the biological activity of
CNTF, 3 rcd1 dogs (rcd1 control group) that were treated following a protocol that achieves
photoreceptor rescue in this model (CNTF injection at 7 and 10 weeks of age, termination at
14 weeks of age). This work, presented in abstract form but never published, served as a basis
for choosing the dose of CNTF that was administered in this study. Treatment Group #3 was
included to determine whether a similar rescue effect would be attained in XLPRA2 dogs
exposed to this same protocol.
The second aim of this study was to determine whether CNTF could cause any alterations in
the retinal cyto-architecture of the XLPRA2 dog. In treatment Groups #1, #2, and #3, CNTF
was injected for the first time before the retina had reached full maturation, thus, treatment
Group #4 was included to examine the remodeling effects of a single injection of CNTF in the
matureXLPRA2 canine retina. To control for disease-specificity, a single non-mutant dog was
treated in the same way as in treatment Group #3 (Inj. 7 & 10 wk; Ter. 14 wk). To further
characterize potential CNTF-mediated cellular alterations a different set of studies was carried
Exp Eye Res. Author manuscript; available in PMC 2009 July 14.
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out. For this, 4 affected XLPRA2 dogs were used following protocols detailed below (see under
“Histologic procedures”, and “Cell proliferation assays” sections).
All intravitreal injections were performed in eyes that had their pupils previously dilated by
topical application of atropine, phenylephrine and tropicamide. Under general anesthesia
(isoflurane), dogs underwent a 1 minute massage of their globes to reduce the intraocular
pressure (IOP). A 29-gauge needle mounted on an insulin syringe was then inserted in the
supero-temporal quadrant approximately 5 mm behind the limbus, and the tip was directed
towards the center of the vitreous to inject in the left eye (OS) 12 μg of CNTF in 0.1 M PBS
(Total volume injected: 30 μl). The right eye (OD) served as a control, and was injected with
30 μl of the PBS diluent. Immediately following the injections, both eyes were examined by
slit-lamp biomicroscopy and indirect ophthalmoscopy to verify that no lesions were caused to
the lens and/or retina during the procedure. All animals underwent additional ocular
examinations 2–4 days following the intravitreal injections and subsequently, at least once a
week, for the remaining of the treatment period. This included IOP measurements by
applanation tonometry (TonoPen XL, Medtronic Ophthalmics, Jacksonville, FL). At the end
of the treatment period, the animals were euthanatized by intravenous injection of pentobarbital
sodium, enucleated, and the eyes processed as indicated below. All procedures involving
animals were done in compliance with the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research.
Histologic procedures
The eyes of the 16 dogs (12 XLPRA2, 3 rcd1, 1 non-mutant) used in the initial part of the study
were processed after enucleation as previously published (Beltran et al., 2006). A slit was made
at the level of the ora serrata, and the entire globe was fixed for 3 hours in 4%
paraformaldehyde in 0.1 M PBS at 4°C. The posterior segment was isolated and fixed for an
additional 24 hours at 4°C in 2% paraformaldehyde. The tissue then was trimmed into four
pieces that extended from the optic disc to the ora serrata along the superior, inferior, nasal,
and temporal meridians. Following sequential cryoprotection for 24 hours in solutions of 15%
and 30% sucrose in PBS at 4°C, the tissues were embedded in optimal cutting temperature
(OCT) medium. Cryosections were cut at 7 or 10 μm thickness, air-dried, and stained with
hematoxylin & eosin (H&E), or used for immunohistochemistry (see below). The anterior
segments of some animals were post-fixed in Bouin’s solution, and paraffin embedded. Paraffin
sections were cut at 6 μm thickness, H&E stained, and used to examine the pathology in the
cornea, iris and lens.
Retinal cryosections stained with H&E were examined by light microscopy (Axioplan; Carl
Zeiss Meditec GmbH, Oberkochen, Germany) in contiguous fields extending from the optic
disc to the ora serrata with 10X and 40X objectives. For each animal, quantitative evaluation
of the outer nuclear layer (ONL) thickness was done on sections from the 4 meridians of both
eyes at 3 specific locations: S1, S2, and S3 (See Figure 1). At each of these sites, the number
of rows of nuclei in the ONL was counted in at least 3 representative areas and averaged. The
field that was viewed with the 40X objective covered a retinal length of 290 μm. Because
alterations in the retinal architecture were frequently seen involving site S3 (see Results), we
excluded ONL data collected at this site, and restricted the analysis of photoreceptor rescue to
the central (S1) and mid-peripheral (S2) regions of the retina. For each quadrant, the average
ONL thickness (mean of ONL thickness at S1 and S2) was calculated, and compared to that
of the contralateral eye. The paired Student t-test was used to analyze the differences in ONL
thickness between the CNTF- and the PBS-injected eyes. Statistical analysis was performed
using a commercial software (Statistix 8; Analytical Software, Tallahassee, FL).
To better detect and characterize potential retinal alterations induced by CNTF, we examined
on semi-thin plastic sections the retinal morphology of two additional XLPRA2 dogs. One dog
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was treated following the same protocol as for Group #1 (Inj. 4 wk, Ter. 8 wk); the second dog
received the same treatment as Group #2 (Inj. 4 & 8 wk; Ter 12 wk). Eyes were collected,
fixed, and trimmed as described above, and processed for epoxy resin embedding as previously
reported (Beltran et al., 2006). Retinal sections extending along all 4 meridians were cut at 1
μm with glass knives using a supercut microtome (Reichert Jung model 2065; Leica, Deerfield,
IL), and stained with azure II-methylene blue with or without paraphenylenediamine
counterstain. For each meridian, the site of highest ONL thickness in the peripheral retina of
the CNTF-injected eyes was located, and its distance from the ora serrata measured. This was
used to locate the corresponding site in the contralateral PBS-injected eye. Using the 40X
objective, digitally captured images (Spot 4.0 camera; Diagnostic Instruments, Inc., Sterling
Heights, MI) that encompassed a 290 μm length of retina, were printed to manually count the
total number of photoreceptor nuclei at these two sites. For each meridian, the counts were
performed in triplicate on sequential sections, and the values averaged.
Immunohistochemistry
Fluorescence immunohistochemistry was used on 7 or 10 μm retinal cryosections of dogs from
all four treatment groups to examine CNTF-mediated modifications with cell-specific markers.
Cryosections were air-dried, blocked in a solution containing 10% normal serum from the
appropriate species, and incubated overnight at 4°C with the primary antibody. Primary
antibodies used in this study are listed in Table 1. Species-specific secondary antibodies
conjugated to fluorochromes (Alexa Fluor, Invitrogen, Carlsbad, CA, 1: 200 dilution) were
then applied to the sections for 1 hour. The antibodies were used at the appropriate dilution in
1.5% normal serum, 0.25% Triton X-100, 0.05% sodium azide in PBS. DAPI stain was used
to label cell nuclei. Slides were mounted with a medium composed of polyvinyl alcohol and
DABCO (1,4 diazabicyclo-[2.2.2]octane) (Gelvatol; Sigma-Aldrich, St. Louis, MO), and
examined with an epifluorescence microscope (Axioplan; Carl Zeiss Meditec). Digitally
captured images were imported into a graphics program (Photoshop; Adobe, Mountain View,
CA) for display. When double fluorescence immunohistochemistry was done, primary
antibodies (followed by their secondary) were applied sequentially.
In order to determine whether the α subunit of the CNTF receptor (CNTFRα) is expressed in
normal and mutant photoreceptors during postnatal retinal maturation, as well as during the
course of retinal degeneration, archival collections of normal and mutant retinas developed by
our lab were used. These included retinas of normal, rcd1, and XLPRA2 dogs (age: 4–24
weeks); some of these tissues have been used in other previous studies (Beltran et al., 2006).
Enzymatic immunohistochemistry was performed on 7 μm thick cryosections from the superior
meridian of these retinas as previously described (Beltran et al., 2003). A rabbit protein Apurified polyclonal antibody raised against a large fragment of the chicken CNTFRα
recombinant protein [1:2,000 dilution; (Holst et al., 1997)] was used for this study. This
antibody cross reacts in the dog as well as in other mammalian species (Beltran et al., 2003;
Beltran et al., 2005).
Cell proliferation assays
To determine whether intravitreally-injected CNTF could cause cell proliferation, we
conducted BrdU pulse-labeling experiments in two XLPRA2 dogs. At 4 weeks of age both dogs
were anesthetized with isoflurane and injected intravitreally in the left eye with 30 μl of a 0.1
M PBS solution containing 12 μg of CNTF and 10 μg of 5-Bromo-2′-Deoxyuridine (Sigma,
St-Louis, MO); the contralateral eye was injected with 30 μl of a 0.1 M PBS solution containing
10 μg of BrdU. The dose of BrdU injected was extrapolated from the dose used in chick eyes
(Fischer and Reh, 2000). Twenty four hours later, one dog was euthanatized and the eyes
processed as described below. The second dog was re-injected under isoflurane anesthesia in
both eyes with 30 μl of a 0.1 M PBS solution containing 10 μg of BrdU at 24 and 96 hours
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following the initial injection. At 5 weeks of age, this animal was killed, and the eyes collected.
Following enucleation, the anterior and posterior segments were separated and the vitreous
was gently removed from the posterior eyecup. The tissues were then fixed for 30 min in 4%
paraformaldehyde with 3% sucrose in 0.1 M PBS at 4°C. Following three washes in PBS,
tissues were cryoprotected, trimmed and embedded in OCT as described above.
Immunohistochemical detection of BrdU incorporation was done on 7 μm cryosections that
were pretreated in 4 M HCl for 10 min, followed by overnight incubation with the primary
monoclonal BrdU antibody (see Table 1). BrdU-positive cells were counted throughout the
entire length (i.e. from optic disc to ora serrata) on a least three retinal sections for each of the
superior, inferior and temporal meridians. Values for each meridian were averaged and
expressed as the number of BrdU-positive cells per unit length of retina. The unit length was
set at 10,000μm. Expression of the nuclear cell proliferation marker Ki67 (Table 1) was also
examined in the retinas of these two dogs by immunohistochemistry.

RESULTS
Clinical findings and CNTF-mediated side effects
Ocular examinations performed immediately after the intravitreal injections did not reveal any
lesions caused by the procedure. Yet, several ocular abnormalities were visible clinically within
a few days following intravitreal injection of CNTF in bothXLPRA2 and rcd1 dogs (Table 2).
None of these changes were seen in any of the PBS-injected eyes. Therefore, the following
description only applies to the CNTF-treated eyes.
Clinical signs of uveitis were the first to appear, and consisted mainly of miosis, intraocular
hypotension, and occasional iridal changes (see below). Aqueous humor flare was not detected
by slit lamp biomicroscopy during the first week following the injection. Later, examination
of the aqueous humor transparency was hampered by development of corneal haze (see below).
Miosis that was refractory to dilatation with topical mydriatics was seen in all dogs that were
reexamined 2 days after the first CNTF injection, and persisted for approximately 2 weeks.
In 2 XLPRA2 dogs (treatment Group # 4) that had lightly pigmented irides, vascular
engorgement was seen 48 hours following injection. Anterior displacement of the iris, causing
a reduction in anterior chamber depth, was also seen 2 days post-injection in 2 rcd1 dogs. An
increase in iris pigmentation was observed in 1 dog (treatment Group #3), and in 3 dogs from
(treatment Group #2), respectively, at 17 and 51 days after the 1st injection of CNTF. Combined
IOP values of XLPRA2 (all treatment groups) and rcd1 dogs, measured between post-injection
days 2–4, were significantly lower (P<0.0001, paired Student t test) in CNTF- injected (mean:
7.1 mm Hg, min:4 mm Hg, max: 12 mm Hg; n= 15) versus PBS-injected (mean: 13.5 mm Hg,
min:8 mm Hg, max:22 mm Hg; n= 15) eyes. All CNTF-injected eyes were hypotensive (IOP
< 8 mm Hg, or IOP at least 5 mm Hg lower than in the PBS-treated eye) after the first or second
injection. A steep decrease in IOP was seen during the first 4–7 days following CNTF injection,
but values returned to pre-injection levels within 20 days. In PBS-injected eyes, a slight
increase in IOP occurred that remained within normal levels [19.2 ± 5.9; (Gelatt and MacKay,
1998)] was observed for 10–14 days following injection. Similarly, IOP values returned to preinjection values within approximately 20 days. Figure 2 illustrates the IOP changes observed
in a subset of the experimental dogs.
Corneal epithelial abnormalities were observed by external and slit-lamp examination in 15/16
of the eyes injected with CNTF (Figure 3A). Discrete lesions that caused a hazy patch in the
corneal epithelium could be observed in some animals as early as 3–4 days following CNTF
injection. By post-injection day 11, the corneal epithelial haze was present in all 15 affected
animals. These epithelial changes progressed with time, and could involve more than 75% of
the corneal surface. However, a peripheral band located in the superior part of the cornea was
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never affected, and remained optically clear. The lesions persisted throughout the entire
treatment period, and were never associated with corneal ulceration. Histological examination
revealed thinning of the epithelium with attenuation of the basal and suprabasilar (wing) cell
layers (Figure 4A,B). No corneal abnormalities were observed in any of the PBS-injected eyes.
Cataracts were commonly observed following CNTF injection (15/16 eyes). Examination of
the lens was hampered during the first 2 weeks by the intense miosis and difficulty in fully
dilating the pupil. By post-injection day 14, posterior sutural cataracts could be observed in
CNTF-injected eyes of XLPRA2 (8/12 eyes), rcd1 (3/3 eyes), and non-affected (1/1 eye) dogs
(Figure 3B). Cataracts often progressed by involving the posterior and anterior cortex (Figure
3C). Histological examination of some cataractous lenses confirmed the predominant
involvement of the posterior suture lines and cortex (Figure 4C, D). No lenticular opacities
were detected in any of the PBS-injected eyes.
A thorough funduscopic examination was difficult to conduct in the CNTF-injected eyes,
initially because of the associated miosis, and later on due to the loss of transparency of the
ocular media caused by corneal epitheliopathy and lens opacities. In those animals in which
areas of the fundus were visible, no abnormalities were detected. One exception was seen in
the non-mutant control dog that had multiple small “doughnut” shaped foci scattered
throughout both the tapetal and non-tapetal regions of the fundus (data not shown). Although
this was an isolated observation in this study, we saw a similar type of lesion in a normal dog
injected with a similar dose of CNTF in a previous pilot study.
Gross examination of the globes at the time of enucleation did not reveal any differences in
size between PBS- and CNTF-injected eyes.
CNTF fails to prevent photoreceptor cell loss in XLPRA2
The average ONL thickness in each quadrant was determined as a means of assessing the
photoreceptor survival effect of CNTF. Using this measure, there was no statistically
significant difference in any of the 4 treatment groups between the CNTF and PBS-injected
eyes (Figure 5 and 6). The mean difference in ONL thickness of 0.90 rows of nuclei (Group
#1: 0.98 ± 0.52; Group #2: 0.77 ± 0.69; Group #3: 0.94 ± 0.63) between the CNTF versus PBStreated eyes also was not biologically relevant. Based on the kinetics of photoreceptor cell loss,
(Beltran et al., 2006) a difference of at least 2 rows of nuclei (treatment Groups #1 and #3),
and 3 rows of nuclei (Group #2), would have been expected in both the superior (Figure 7) and
inferior meridians if CNTF had caused a complete rescue of photoreceptors from the time of
the first injection. Further confirming the absence of any significant neuroprotective effect of
CNTF in the XLPRA2 retina was the presence of morphological alterations at the level of the
photoreceptor inner (IS) and outer (IS) segments that were characteristic of the disease.
Disruption of the OS, shortening and broadening of the IS, and reduction of the subretinal space
was seen in all groups, either CNTF- or PBS-treated, suggesting that the natural course of the
disease had not been arrested or modified.
In the rcd1 control group, we observed a statistically significant rescue of photoreceptors with
CNTF (Figure 5 and 6) The mean (± SD) difference in ONL thickness between the CNTF and
PBS injected retinas was of 1.5 ± 0.56 rows of nuclei, and consistent with findings previously
observed (Pearce-Kelling, unpublished). In the 7 week-old rcd1 retina, the ONL has already
lost approximately 40% – 50% of its photoreceptors, and has an average thickness of 5 to 6
rows of nuclei along the superior meridian (Schmidt and Aguirre, 1985). In this study, the mean
ONL thickness of the superior retina at 14 weeks of age was 4.4 and 2.5 rows of nuclei in the
CNTF- and PBS-injected eyes, respectively. This indicates that although statistically
significant, there is not a total rescue of photoreceptor cells in this model following an
intravitreal injection of CNTF at 7 and 10 weeks of age.
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To determine whether the lack of CNTF-mediated rescue in XLPRA2 could be explained by
the absence of expression of the α subunit of the CNTF receptor, immunolocalization of
CNTFRα was done on retinas from XLPRA2 as well as in rcd1 and normal dogs, at ages ranging
from 4 to 24 weeks. The pattern of labeling was similar to that previously reported for the
normal adult canine retina (Beltran et al., 2003), and was characterized by an intense staining
of the IS, inner nuclear layer (INL), ganglion cell layer (GCL) and nerve fiber layer (NFL). At
the earliest age examined (4 weeks; Figure 8 A1–A3), CNTFRα-immunoreactivity was present
in both rod and cone IS. With progression of both diseases, the shortening of rod IS, and their
subsequent disappearance, photoreceptor labeling was restricted to the remaining cone IS
(Figure 8 B2, C2, C3).
CNTF causes peripheral remodeling in XLPRA2 retinas
A consistent finding in all 4 quadrants of CNTF-injected eyes of XLPRA2 dogs enrolled in
treatment Groups #1, #2, and #3 was abnormal changes in the retinal periphery. These
alterations included a loss of IS and OS, an increase in ONL thickness, and misplaced rod-like
nuclei in the INL (Figure 9 and Table 3). These changes were disease- (XLPRA2) and agespecific, since they were not present in either the rcd1 control group, the single non-mutant
dog, or the XLPRA2 mutants treated for the first time at 12 weeks of age (Group #4).
A remarkable feature associated with peripheral ONL remodeling was the loss of both
photoreceptor IS and OS that caused, in some areas, the retinal pigment epithelium (RPE) to
be in direct apposition with the external limiting membrane (ELM) (Figure 9 A2, B2, C2). This
loss of the photoreceptor layer (PRL) extended over distances (labeled “l” in Table 3) that were
usually shorter, although occasionally equal, than the lengths (labeled ”L” in Table 3) over
which an increase in ONL was noted. In animals from Group #4, there was rarely a complete
loss of the PRL, yet loss of OS and significant shortening of IS was occasionally seen (Figure
9 D2).
When combining results from all 4 meridians of treatment Groups #1, #2, and #3 (Table 3),
the mean distance (L) from the ora serrata over which an increase in ONL thickness could be
observed in the CNTF-treated eye was L:2,075 μm (L min: 500 μm; L max: 5800 μm). The
longest expanse of altered ONL was seen in the superior meridian, and then in the inferior
meridian. The peripheral ONL remodeling was most extensive in animals from treatment
Group #2. The increase in ONL thickness was associated with an increase in spacing between
nuclei, such that the density of photoreceptors appeared to be reduced following CNTF
injection. Because of this, and due to the misalignment of layers of photoreceptor nuclei, the
thickness of the ONL was measured in micrometers rather than in number of rows of nuclei.
This was done at the site of highest ONL thickness (Labeled “D” in Table 3). If, an equal
increase in ONL thickness was observed throughout an extended length of ONL, the area that
was selected for analysis was the one located the furthest distance from the ora serrata. At that
site, there was a 1.94 fold average increase (R min: 1.22; R max: 3) in ONL thickness following
CNTF admistration in comparison to the corresponding region of the PBS-treated eye [Figure
9 and Table 3 (“R” ratio)].
Finally, misplacement of rod-like nuclei in the outer plexiform layer (OPL) and INL caused a
disorganization of the typical layering of the retina. A wavy aspect of the vitreal edge of the
ONL was responsible for the frequent loss of a clear delimitation by the OPL of both nuclear
layers (Figure 9 A2, B2).
To determine the nature of the cell population(s) responsible for this apparent increase in cell
number in the ONL, immunohistochemical studies were performed using several cell-specific
markers on XLPRA2 retinas from all 4 treatment groups. The results confirm that the
overwhelming majority of cells present in the peripheral ONL, and migrating to the INL of
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CNTF-treated eyes (Groups #1–3), are rod opsin-positive (Figure 10 A2). Although we have
previously shown in XLPRA2 (Beltran et al., 2006) a mislocalization of rod opsin to the soma
and axons of rods (see Figure 10 A1) similar to that reported by others (Li et al., 1995), this
was more pronounced in retinas examined 4 to 8 weeks after CNTF treatment. In addition, in
contrast to what is seen in the untreated XLPRA2 retina (Beltran et al., 2006), there was absence
of rod opsin labeling in rod OS and IS in the periphery, thus, further confirming the loss of
these structures following CNTF treatment (Figure 9 A2). The use of a cone arrestin antibody
also confirmed the presence of heterotopic cone somas in the middle and inner portions of the
ONL. These cells had neither an axon nor an IS (Figure 10 A2). One week following the
injection of CNTF in a 4 week-old XLPRA2 retina, the migration of cone somas down their
axon was seen in the periphery (Figure 10 B3).
Rod opsin and cone arrestin immunoreactivities were also examined in XLPRA2 retinas 1 and
7 days following an injection of CNTF, and a significant decrease in intensity of labeling was
seen in comparison to the PBS-injected eye (Figure 10 B1, B2). This decrease in rod opsin and
cone arrestin expression which was more pronounced 1 week post-CNTF injection was seen
throughout the entire length of the retinal sections, but was most prominent in the periphery.
This reduction in immunoreactivity was not present 4 weeks after the injection.
Peripheral remodeling of the retina also involved cells of the INL. The use of cell markers for
bipolar cells showed significant dendritic sprouting into the peripheral ONL, as well as
heterotopia of PKCα/Goα-positive cells (two markers for rod bipolar cells) (Figure 10 C1,
C2). Similarly, radial extension into the ONL of processes originating from calretininimmunoreactive horizontal cells was observed in the peripheral retina (Figure 10 D1, D2).
CNTF treatment also caused misplacement in the ONL of the somas of some CRALBP-positive
Müller cells (Figure 10 E1, E2). Glial fibrillary acid protein (GFAP) immunoreactivity was
also examined and showed a similar labeling of the entire cell body of Müller cells (data not
shown) in both CNTF- and PBS-treated eyes. This is not surprising since GFAP activation of
Müller cells is known to occur at the ages examined (Beltran et al., 2006).
CNTF causes an increase in cell number in the peripheral XLPRA2 retina
To determine whether the thickening of the ONL was caused solely by increased internuclear
spacing, or by a higher number of ONL cells, plastic embedded retinal sections of two
XLPRA2 dogs were examined; each dog was treated using the same protocols as for Group #1
(Inj. 4 wk; Ter. 8 wk), and Group #2 (Inj. 4 & 8 wk; Ter. 12 wk), respectively. These 1-μm
thick sections permitted individual cell counts (Figure 11) which could not be done on the
thicker (7 or10 μm) cryosections where substantial overlap of nuclei occurred. Examination
of the peripheral retina of the CNTF-treated eyes confirmed that there was more space between
the photoreceptor nuclei, although it could not be determined whether this resulted from intraor extracellular swelling. Elevation of the external limiting membrane, suggesting cytoplasmic
swelling of photoreceptors or Müller cell processes, has been reported in both rcd1 and nonmutant dogs implanted with a long-term CNTF release device (Zeiss et al., 2006). This was
not observed in the current study. In addition to heterotopic rod nuclei in the INL (Figure 11
C2; arrows), there were cells with larger nuclei within the thickness of the ONL (arrowheads).
These nuclei contained fewer chromatin clumps than rods, and resembled that of cones. Nuclear
count in both CNTF- and PBS-injected eyes was done at the site of highest ONL thickness as
described above. Although statistical analysis could not be done due to the limited number of
observations, we observed a consistently higher number of cells in the CNTF-treated peripheral
retina (Table 4).
To determine how early following an injection of CNTF an increase in ONL thickness is
observed in the peripheral XLPRA2 retina, and to determine if this is caused by cell
proliferation, BrdU pulse labeling and Ki67 immunohistochemical studies were performed in
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two dogs. No major differences in ONL thickness, BrdU incorporation, or Ki67
immunolabeling were observed 24 hours following CNTF injection (data not shown). Yet, a
major increase in ONL thickness was observed in the dog whose retina was collected one week
post-CNTF administration (Figure 12A, B). Although BrdU incorporation was seen in cells
located at the peripheral retinal margin (Figure 12 D1, D2), and in the NFL, GCL, and INL
throughout the entire length of the retina of both CNTF- and vehicle-treated eyes, there was a
higher number of BrdU-positive nuclei with CNTF (Table 5). Indeed, combining results from
three meridians, a mean of 47 and 135 cells per 10,000 μm of retina length, was found in the
PBS- and CNTF-injected eyes, respectively. In addition, rare BrdU-positive cells were found
exclusively in the ONL of the CNTF-treated retina (Figure 12 D3). A similar finding was
observed with Ki67 (Figure 12 E2).

DISCUSSION
XLPRA2 is an early onset model of X-linked retinitis pigmentosa characterized by an early
burst of photoreceptor cell death that begins at 4 weeks of age and reaches a peak at 7 weeks.
This event is followed by a more gradual loss of rods and later of cones that persists for over
9 months (Beltran et al., 2006). An attempt to rescue photoreceptors from this initial phase of
cell death with intravitreal injections of CNTF failed to promote in XLPRA2 a similar
neuroprotective effect as seen in the rcd1 dog (Tao et al., 2002). A peculiar set of findings that
were exclusively observed in XLPRA2 consisted of remodeling of the retinal periphery and an
increase in cell number in the ONL. In addition, ocular toxic effects that involved the cornea,
lens, and uveal tract were seen in both mutants and normal dogs.
Intravitreal injection of survival factors in animal models of RP has been used routinely to
establish proof of principle of their photoreceptor rescue properties (LaVail et al., 1992). Yet,
a recognized limitation to this route of administration for the treatment of retinal degenerations
is the short half-life of these agents (Cayouette et al., 1999), and their associated ocular sideeffects (Faktorovich et al., 1990; Faktorovich et al., 1992; Lewis et al., 1992; Perry et al.,
1995). In this study, corneal epitheliopathy, cataracts, and clinical signs of uveitis were
observed within a few days following a single intravitreal injection of 12 μg of CNTF. Similar
clinical findings were observed in the rcd1 dog (Pearce-Kelling, unpublished) and Rdy cat
(Chong et al., 1999) treated with Axokine® (Regeneron, Tarrytown, NY), a recombinant
mutein of human CNTF. These side-effects appear to be dose-related because they are not seen
in rcd1 dogs that are intravitreally implanted with a long-term delivery device that releases a
daily dose approximately 1000 fold lower (Tao et al., 2002).
Several hypotheses may explain the absence of a positive rescue effect in photoreceptors of
the XLPRA2 dog: 1) A lack of activation of intracellular signaling pathways may be responsible
for the absence of a survival response. This study showed that the α subunit of the CNTF
receptor (CNTFRα) was expressed throughout the course of retinal degeneration in rcd1 and
XLPRA2, but we did not investigate whether CNTF triggered any cell signaling pathways.
Therefore, it is not known whether the binding of CNTF to CNTFRα activates the same
molecular signaling cascades in both diseases. 2) The activation of anti-apoptotic molecules
may not interfere with the molecular mechanisms of cell death that are involved in XLPRA2.
Identifying the key molecular events that occur in different models of photoreceptor
degeneration may reveal a spectrum of cell death pathways that respond differentially to
survival factors. This may be the basis for the difference in response between rcd1 and
XLPRA2, and could explain CNTF’s positive rescue effect in the rd/rd, nr/nr and Q344 ter
mice, and its absence in the rds/rds, pcd/pcd, P23H and VPP mice (LaVail et al., 1998). 3) In
the mutant, there may be activation of a stimulus so detrimental to the cell’s homeostasis that
its effects can not be countered by the survival factor. We intentionally chose to target the
initial burst of photoreceptor cell death that occurs between 4 and 7 weeks of age in
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XLPRA2 (Beltran et al., 2006) as an approach to inhibit as early as possible the onset of the
disease, and rescue the highest number of cells. However, this may not have been the optimal
time-window for therapy, if the putative toxic gain of function caused by the RPGR frameshift
mutation is at its highest level during this period. 4) Finally, we cannot exclude the possibility
that bolus intravitreal injections of CNTF may not be the optimal route of administration to
detect a potent rescue effect in this model. The rate of cell loss in XLPRA2 is rapid, yet slightly
slower than that observed in rcd1; and a rapid elimination of CNTF from the eye may have
prevented the prolonged activation necessary to elicit a full rescue response in this model. The
treatment of XLPRA2 retinas with CNTF caused a mild increase in ONL thickness (~ 1 row of
nuclei) in comparison to that obtained with PBS. Yet, this difference was below that expected
from a total rescue, and, within the time-window of this study, may not be biologically relevant.
Confirmation of a potential neuroprotective effect in XLPRA2 would require the use of a longterm delivery device to achieve sustained bioavailability of CNTF over a longer period of time.
Quantitative methods were not used to measure the levels of expression of rod opsin and cone
arrestin, yet immunohistochemical results suggested that CNTF caused a rapid but transient
decrease in the expression of these two proteins. It was seen as early as 24 hours following the
injection, and was more pronounced 7 days later. Several groups have reported that CNTF
causes a transient and reversible inhibition of rhodopsin in postmitotic opsin-negative rod
precursor cells in rodents (Ezzeddine et al., 1997; Neophytou et al., 1997; Kirsch et al.,
1998; Caffe et al., 2001; Schulz-Key et al., 2002; Zahir et al., 2005). However, a significant
difference between these studies and our, is that we tested the effect of CNTF on photoreceptors
that are at a more advanced stage of development. At 4 weeks of age in the canine retina,
photoreceptors although not fully mature (IS are budding) already express rod opsin and cone
arrestin. Thus, the effect of CNTF reported in the present study appears to be a down-regulation
of phototransduction proteins rather than an arrest in rod development. This negative regulation
in the expression of phototransduction proteins has been also reported in mature photoreceptors
of the normal rat (Song et al., 2005), and rcd1 dog (Zeiss et al., 2006) following intravitreal
administration of CNTF. Such an effect may be responsible for the electroretinographic
alterations reported in rat and mouse models of retinal degeneration, as well as in the normal
albino rabbit following intraocular delivery of CNTF (Bush et al., 2000; Liang et al., 2001;
Bok et al., 2002; Schlichtenbrede et al., 2003).
Retinal remodeling associated with photorececeptor degeneration as been reported by several
groups in humans with RP (Fariss et al., 2000; Jones et al., 2003), as well as in animal models
(Strettoi and Pignatelli, 2000; Fisher and Lewis, 2003; Marc et al., 2003; Pignatelli et al.,
2004; Jones et al., 2005; Beltran et al., 2006). In this study, a striking finding was the prominent
remodeling that occurred in the peripheral retina of XLPRA2 dogs following intravitreal
injection of CNTF. These retinal alterations consisted of loss of IS and OS, neuronal sprouting,
heterotopia of retinal cells, and increase in the number of rods that contributed to the thickening
of the ONL. The changes were disease- and age-specific. Indeed, they were only observed in
XLPRA2 dogs, and only if the first intravitreal injection of CNTF was done no later than at 7
weeks, an age at which the normal canine retina is reaching full maturation (Farber et al.,
1992).
The disorganization in the normal retinal layering was associated with the loss of inner and
outer segments, which has been also observed by others (Schlichtenbrede et al., 2003; Song et
al., 2005), Similar alterations were found in the retinas of transgenic mice that constitutively
express leukemia inhibitory factor (Graham et al., 2005; Sherry et al., 2005). Although IS are
beginning to bud in the 4 week-old canine peripheral retina, IS and OS are fully formed when
the retina has reached maturity at 7–8 weeks of age. CNTF, therefore, may have prevented the
formation of IS and OS when injected at 4 weeks of age (treatment Groups #1 and #2), and
caused their loss when injected later in 7 week-old dogs (treatment Group #3). Our findings
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suggest that CNTF may not only arrest photoreceptor maturation when administered at 4 weeks
of age in the XLPRA2 dog, but also cause them to loose structural and molecular markers that
are characteristics of a mature photoreceptor. We propose that the loss of these phenotypic
markers may represent a form of dedifferentiation. To the best of our knowledge we are
unaware of reports of such a process in photoreceptor cells, yet, this is not unexpected since
CNTF has recently been shown to induce the dedifferentiation of adult human myoblasts into
multipotent progenitor cells (Chen et al., 2005), as well as the transformation of striatal
astrocytes toward a more immature and activated phenotype (Escartin et al., 2006).
CNTF is known to elicit the formation of new neuritic processes in rodent motor neurons and
this process is currently being investigated as a potential approach to treat partial denervation
and neuromuscular paralysis (Gurney et al., 1992; Siegel et al., 2000). More recently, it was
reported that gene delivery of CNTF in a feline model causes neurite extension from rods,
bipolar, and horizontal cells, and such a process may be seen as a detrimental effect (Sethi et
al., 2005). We observed in this study a similar effect in the XLPRA2 dog. This may be caused
by an alteration in neurotransmission at the synaptic terminal between rods, horizontal, and
bipolar cells, as a result of a negative regulation on the phototransduction pathway. Another
feature of the retinal remodeling that took place in the periphery was heterotopia of some rod,
cone, bipolar, and Müller cell somas. These findings share some similarities with observations
made in mouse and rat retinas exposed in vitro to CNTF. In these species there is currently still
some controversy as to whether CNTF causes a phenotypic “switch” by turning rod precursor
cells into bipolar cells (Ezzeddine et al., 1997; Zahir et al., 2005), or whether it transiently
inhibits rod opsin expression and increases the expression of bipolar cell markers in rod
precursor cells (Neophytou et al., 1997; Kirsch et al., 1998; Schulz-Key et al., 2002). In our
study the origin of the PKCα/Goα and CRALBP positive cells located in the ONL remains
unknown. These could be rod precursor cells that have undergone a change in cell fate, mature
rods that have lost some of their specific photoreceptor markers and now express bipolar or
glial cell markers, or alternatively, mature bipolar neurons and Müller cells that have migrated
to an ectopic location. We do provide evidence that misplaced cones represented somas that
had moved down the cone axon.
The most prominent feature of the peripheral remodeling was the abnormal increase in ONL
thickness that has also been reported in normal rabbits implanted with ECT devices secreting
a high dose (22ng/day) of CNTF (Bush et al., 2004). In the present study, the thickened ONL
could be seen extending several millimeters away from theora serrata, and was detected as
early as one week following CNTF administration. Although this was undoubtedly associated
with some degree of intra- and/or extracellular swelling, an increase in the number of rod opsinpositive cells was the major contributing factor. The extent of the increase in cell number could
not be explained only by a neuroprotective effect. The use of cell proliferation markers
confirmed that CNTF caused a higher number of cells to enter the cell cycle. Yet, the number
of BrdU- or Ki67-positive cells that were found in the ONL was limited, and could not account
completely for the supernumerary nuclei seen in this layer. The most plausible explanation for
this discrepancy has to do with the period of cell proliferation, and the time-points at which
tissues were collected. It is indeed possible that, despite doing repeated injections of BrdU, a
high enough concentration may not have been attained at the optimal time for its incorporation.
Similarly, one week following CNTF injection, the great majority of these cells may have
exited the cell cycle and were no longer Ki67-positive. Addressing this issue would require
determining the precise time of onset of the cell proliferation, and performing additional BrdU
pulse-labeling experiments. This will be the subject of future studies.
The increased number of cells in the ONL raises the question of their origin. Although there
is recent evidence for the presence of retinal progenitor cells at the retinal margin of ptc+/−
mice (Moshiri and Reh, 2004), monkeys, and humans (Cuenca et al., 2005), it is unlikely that
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neurogenesis in this zone may account for all the additional cells that are seen over distances
as far as 5,800 μm from the ora serrata. Recently, a pool of mitotic retinal progenitor cells was
found distributed in the central retina of the adult Chx10−/− mouse (Dhomen et al., 2006).
Therefore, it may be possible that in XLPRA2, CNTF induces proliferation of such precursor
cells (Zhang et al., 2005). Finally, another possibility is that CNTF causes rods to
dedifferentiate and subsequently re-enter the cell cycle. The elimination of CNTF from the eye
would cause the cells to stop proliferating, and assume a more differentiated phenotype.
The increase in cell number in the retinal periphery raises the question as to whether this
response represents a rescue effect. We do not consider it to be neuroprotection because such
a mechanism of cell survival implies the preservation of existing cells in a differentiated state
and without proliferation. If proliferation could be considered beneficial, it would require that
the proliferated cells differentiate; a situation that was not observed in this study.
In summary, this study shows that intravitreal injection of CNTF does not prevent the early
phase of cell death that occurs in a canine model of X-linked retinitis pigmentosa caused by a
frameshift mutation in RPGR exon ORF15. Whether CNTF can rescue photoreceptors from
the later phase of degeneration now needs to be addressed. This should provide further evidence
as to whether human patients with similar mutations in RPGR would be expected to respond
to this specific neuroprotective agent. CNTF also caused substantial remodeling in the
peripheral retina of XLPRA2 dogs. These peripheral alterations are most likely age-, dose-, and
disease-specific. They were only observed when CNTF was injected before the canine retina
had reached full maturation. Therefore, although this may not be an issue for adult human
patients treated with sustained release of CNTF (Sieving et al., 2006), peripheral retinal changes
observed in normal adult rabbits (Bush et al., 2004), and the suggestion that endogenous
secretion of CNTF may be the cause of cell proliferation in humans with mutations in the
NR2E3 gene (Jacobson et al., 2004) warrants further investigation.
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Figure 1.

Schematic of a retinal section showing the location of the sites S1, S2, and S3. S1: 2000 ± 500
μm from the optic disc; S3: 2000 ± 500 μm from the ora serrata; S2: equidistant (± 500 μm)
from S1 and S3.
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Figure 2.

Values (mean, and range) of intraocular pressure in CNTF- and PBS-treated eyes. Data is
provided for dogs from treatment Group #3 (XLPRA2; n=3), and rcd1 control group (n=3) that
were injected at 7 and 10 weeks of age. Pre-injection values of intraocular pressure are indicated
at time 0. In the days following both CNTF injections a decrease in IOP was observed. The
intraocular hypotension was transient, since IOP values returned to pre-injection values within
approximately 20 days.
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Figure 3.

Ocular lesions caused by intravitreal injection of CNTF. (A) Corneal epithelial haze
(arrowheads), and posterior subcapsular cataracts (arrows) 7 weeks post-injection. A corneal
haze and sutural cataract had been detected in this dog 11 days following the first CNTF
injection. (B) The earliest lens changes involved the extremities of the posterior Y sutures
(arrows). (C) Immature cataract with anterior and posterior cortical opacification.
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Figure 4.

Histological lesions of the cornea and lens present after intravitreal injection of CNTF. (A)
Normal aspect of the corneal epithelium in a PBS-injected eye. Note the presence of normal
basal cells (arrows). (B) Cornea of the contralateral eye that was injected with CNTF. Note
the thinning of the corneal epithelium due to the loss of the basal and suprabasilar (wing) cells.
(C) Cataract caused by CNTF. Swelling and disorganization of lens fibers was observed in the
posterior cortex, and was associated with the retention of lens fiber nuclei (arrows). (D) High
magnification of the posterior subcapsular region of the same lens as in (C). Note the presence
of large vacuoles that contain eosinophilic material (asterisks), and swollen lens fibers. H&E
stain; scale bars: (A, B) 20 μm; (C) 80 μm; (D) 40 μm.
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Figure 5.

Scatter plots comparing the ONL thickness (mean number of rows of nuclei at S1 and S2 sites
combined) along the four meridians of eyes injected with CNTF or PBS. No statistically
significant difference in ONL thickness was seen in any of the XLPRA2 treatment Groups #1
– #3. CNTF caused a statistically significant increase in ONL thickness in rcd1. *: < 0.05; **:
< 0.001; ND: not determined; OS: left eye; OD: right eye.
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Figure 6.

Illustration of the effect of CNTF on outer nuclear layer thickness in the mid-peripheral retina
(Site S2) of a 14 week-old XLPRA2 dog (treatment Group #3) (A2), and a 14 week-old rcd1
dog (rcd1 control group)(B2). Contralateral eyes served as controls and were injected with PBS
(A1, B1). CNTF caused an increase in the number of photoreceptor nuclei in rcd1 (compare
B2 to B1), but no differences were seen in XLPRA2 (compare A2 with A1). CNTF often caused
the vitreal border of the ONL to appear wavy (A2, B2). On these cryosections, RPE separation
from the neuroretina was an artifact. H&E stain; scale bars: 20 μm.
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Figure 7.

Rate of photoreceptor cell loss in the XLPRA2 retina as a function of age. ONL thickness was
measured as the number of rows of photoreceptor nuclei. The figure illustrates for the superior
meridian the expected decline in ONL thickness in the absence of a photoreceptor rescue effect
for each treatment Group #1, #2, and #3 between the time of 1st injection and termination.
Double headed arrows and numbers show the expected change in number of nuclei between
these 2 time points for each treatment group. Note that treatment Groups #2 and #3 received
a second injection, respectively, at 8 and 10 weeks of age. Modified (with permission) from
Figure 2A in Beltran et al. IOVS, 2006; 47: 1669–1681.
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Figure 8.

Immunohistochemical localization of CNTFRα in the retinas of normal, rcd1, and XLPRA2
dogs of different ages. Strong immunoreactivity for CNTFRα was seen in the GCL, INL and
inner segments (IS, arrows) in the normal and mutant retinas at 4 weeks of age (A1–A3). At 8
weeks of age, intense labeling is seen throughout the IS of rods and cones in the normal retina
(B1). In the mutant retinas, labeling persists in the IS of both rods and cones in XLPRA2 (B3),
but is essentially limited to cone IS in rcd1 which is the predominant cell class remaining in
the PRL at this stage of disease (B2). (C1–C3) At 24 weeks of age, CNTFRα-positive cone IS
and somas are still seen in rcd1 and XLPRA2 despite substantial loss of photoreceptors.
Negative controls (A4, B4, C4) were XLPRA2 retinas that were treated with the omission of
the primary antibody. Scale bars: 20 μm.
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Figure 9.

Illustration of the morphologic changes observed in the peripheral retina of XLPRA2 dogs
following intravitreal injection with CNTF. An example from each of the 4 treatment groups
is shown at the site where the measured ONL thickness was maximal. This same location in
the contralateral (PBS-injected eye) is shown for comparison. The boxed areas in the low power
photographs are shown in higher magnification. (A1, A2) Inferior periphery (1,000 μm from
the ora serrata) in an 8 week-old dog (Z263; treatment Group #1). (B1, B2) Superior periphery
(3,900 μm from the ora serrata) in a 12 week-old dog (Z259; treatment Group #2). (C1, C2)
Temporal periphery (550 μm from the ora serrata) in a 14 week-old dog (Z272; treatment
Group #3). (D1, D2) Superior periphery (680 μm from the ora serrata) in a 15.6 week-old dog
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(Z288; treatment Group #4). Note the prominent increase in ONL thickness in dogs from
Groups #1–3 (A2, B2, C2), and the misplacement of rod-like nuclei in the INL (A2, B2;
arrows). No significant difference in ONL is seen in Group #4 (D1, D2). A loss of the
photoreceptor layer (PRL) is seen in Groups #1–3, which causes the external limiting
membrane to be in direct contact with the retinal pigment epithelium (A2, B2, C2; asterisks).
Cryosections; H&E stain; scale bars: 100 μm.
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Figure 10.

Immunohistochemical characterization of CNTF-mediated remodeling of the peripheral retina
of XLPRA2. (A1, A2, B1, B2) Double immunofluorescence labeling of rods and cones with,
respectively, anti-rod opsin (green) and anti-cone arrestin (red), in a 12 week-old dog, 8 weeks
after the first CNTF injection (Group # 2; A1, A2), and in a 5 week-old animal one week postCNTF injection (B1, B2). No labeling is seen at the level of the PRL due to the loss of inner
and outer segments (A2; asterisks). The majority of the cells found in the ONL are rod opsinpositive due to the increased mislocalization caused by CNTF (A2). Rod opsin immunoreactive
cells are seen misplaced in the INL (arrows), and cone arrestin-labeled somas are present within
the thickened ONL (arrowheads). One week following CNTF injection, there is a significant
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decrease in rod opsin and cone arrestin expression (compare B2 with B1 which were taken at
the same exposure settings). Digitally increasing the red fluorescent signal in an area of (B2)
shows the displacement of cone somas (arrowheads) down their respective axons (arrows;
B3). (C1, C2) Double immunofluorescence labeling of ON bipolar cells with anti-Goα (red),
and rod bipolar cells with anti-PKCα (green) in a 12 week-old dog 8 weeks after the first CNTF
injection (Group # 2). DAPI (blue) was used as a nuclear counterstain. Rod bipolar cells are
co-labeled with both antibodies and appeared yellow-orange, whereas ON cone bipolar cells
were only labeled with anti-Goα and appeared red. Note the neuritic sprouting extending into
the ONL (arrows), and the presence of Goα- and PKCα-positive somas in the ONL
(arrowheads) of the CNTF-treated eye. (D1, D2) Immunofluorecence labeling of horizontal
and amacrine cells with anti-calretinin in a 12 week-old dog (Group #2) 8 weeks after the first
CNTF injection. There are radial extensions into the ONL of neurite sprouts originating from
the horizontal cells (arrows) in the CNTF-treated eye. (E1, E2) Immunofluorescence labeling
of Müller cells with anti-CRALBP in a 12 week-old dog (Group #2) 8 weeks after the first
CNTF injection. Müller cell somas are seen misplaced into the ONL (arrowheads) in the
CNTF-treated eye. Note the intense normal CRALBP labeling in the RPE. Scale bars: 20 μm.
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Figure 11.

Changes in the ONL of the inferior periphery in an 8 week-old XLPRA2 dog following
intravitreal injection of CNTF (PBS in the contralateral eye) at 4 weeks of age. Note the increase
in ONL thickness (Compare A and B). The 1 μm thin epoxy resin sections enabled counts of
individual cells in the ONL (C1, C2). Rod-like nuclei were seen in the INL (arrows), and larger
euchromatic nuclei with a cone-type morphology were found in deeper layers of the ONL
(arrowheads). Azure II-methylene blue stain with PPDA counterstain; scale bars: (A, B) 100
μm; (C1, C2) 20 μm.
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Figure 12.

Evidence for cell proliferative events in the peripheral ONL of XLPRA2 following intravitreal
injection of CNTF. (A–D) One week after CNTF injection there was increased ONL thickness
in a 5 week-old dog. Note also the extended loss of the PRL (B, and C2, asterisks). (D1–D3)
Fluorescence immunohistochemical labeling for BrdU (green) shows incorporation in the
ciliary epithelium of the pars plana (D1, D2, arrowheads), and in cells located at the retinal
margin (D1, D2, arrows) in both the CNTF- and PBS-injected eye. (D3) BrdU incorporation
was detected in cells located in the INL (arrowhead), GCL and NFL in both eyes, but few
BrdU-positive cells were seen only in the ONL of the CNTF-treated eye (arrow).
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(E1, E2) Fluorescence immunohistochemical labeling for the nuclear cell marker of
proliferation Ki67 (red). (E2) Ki67-positive cells were seen exclusively in the ONL of the
CNTF-treated eye (arrows), but Ki67 positive cells were found in other retinal layers in both
PBS-and CNTF-injected eyes. Scale bars: (A, B) 100 μm; (C1-E2) 20 μm.
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Table 1

List of primary antibodies used.

Antigen

Host

Source, catalog # or
name

Working concentration

Specificity

Rod opsin

Mouse monoclonal

Paul Hargrave, R2-12N

1:300

OS of rods

Rod opsin

Mouse monoclonal IgG1

Chemicon, MAB5316

1:1,000

OS of rods

Human cone arrestin

Rabbit polyclonal

Cheryl Craft, LUMIF

1:10,000

Cone photoreceptors

Protein Kinase C (PKCα)

Mouse monoclonal IgG2b

BD Biosciences, 610107

1:100

Rod bipolar cells

Goα

Mouse monoclonal IgG1

Chemicon, MAB3073

1:5,000

ON (rod and cone)
bipolar cells

Calretinin

Rabbit polyclonal

Sigma, C7479

1:500

Horizontal,
amacrine, ganglion
cells

CRALBP

Rabbit polyclonal

John Saari

1:1,500

Müller cells, RPE

Glial fibrillary acidic
protein (GFAP)

Rabbit polyclonal

DakoCytomation, Z0334

1:1,000

Astrocytes, Müller
cells (reactive)

CNTFRα

Rabbit polyclonal

Hermann Rohrer

1:2,000

IS of rods & cones,
INL, GCL

Bromodeoxyuridine (BrdU)

Mouse monoclonal IgG1

Chemicon, MAB4072

1:100

Cells that have
incorporated BrdU

Ki67

Mouse monoclonal IgG1

BD Biosciences, 550609

1:20

Proliferating cells
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Table 2

0
0

Corneal epitheliopathy

Cataract

0

Iris hyperpigmentation
0

0

Iris vascular congestion

Intraocular hypotension

0

Miosis

Clinical observations

OD (n =
3)

Group 1

3

3

3

3

0

3

OS (n =
3)

0

0

0

0

0

0

OD (n =
3)

Group 2

3

3

3

3

0

3

OS (n =
3)

0

0

0

0

0

0

OD (n =
3)

Group 3

3

3

3

0

0

3

OS (n =
3)

0

0

0

0

0

0

OD (n =
3)

Group 4

2

3

3

0

2

3

OS (n =
3)

0

0

0

0

0

0

OD (n =
3)

3

3

3

0

0

3

OS (n =
3)

rcd1 control

Summary of clinical findings observed in eyes following intravitreal injection with CNTF (OS) or PBS (OD). Numbers for each category
reflect the number of dogs affected in each treatment group.
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800

l
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/

/

/

/

D

R

/
/

L

1,200

(75/41)

1,350

l

(80/39)

1,000
1.83

D

3,300
1,800

2.05

1,250

L

R

2,300
2,000

l

1.67
(87/52)

3,400

4,700

1.48

2,350

D

Z263

Group 1 (Inj 4; Ter 8)

(68/46)

3,200

L

R

Z262

ID

/

/

/

/

/

/

/

/

300

(44/26)

1.69

400

1,000

700

(72/39)

1.85

1,000

1,300

Z264

600

(36/29)

1.24

500

750

/

/

/

/

2,100

(61/38)

1.61

2,000

3,000

3,800

(62/39)

1.59

3,550

5,200

500

(57/25)

2.28

650

900

/

/

/

/

1,350

(72/30)

2.40

1,350

3,200

3,900

(71/38)

1.87

3,900

5,800

Z259

550

(69/23)

3

600

850

/

/

/

/

600

(68/30)

2.27

550

1,400

3,800

(63/34)

1.85

3,800

4,500

Z260

Group 2 (Inj 4&8; Ter 12)
Z258

700

(60/24)

2.5

550

1,000

800

700

(38/26)

1.46

1,100

1,400

1,200

1.53
(46/30)

2.77

1,100

1,200

1,400

(41/29)

1.41

1,100

1,400

2,200

(44/36)

1.22

2,000

2,200

(61/22)

700

1,300

400

(61/26)

2.35

650

1,900

1,900

(67/33)

2.03

1,500

2,650

Z273

600

(39/18)

2.17

600

900

950

(56/25)

2.24

900

1,150

1,200

(43/19)

2.26

1,350

1,500

2,700

(72/26)

2.77

2,150

2,700

Z274

Group 3 (Inj 7&10; Ter 14)
Z272

0

0

None

None

0

/

/

/

/

0

None

None

0

0

None

None

l:Length of retina (measured in μm from the ora serrata) over which there is a loss of IS and OS in the CNTF-treated eye in comparison to the PBS-treated eye.

R: ratio of ONL thickness in the CNTF-treated eye over the ONL thickness in the PBS-treated eye at distance D from the ora serrata.

D: distance from the ora serrata (measured in μm) of the site of highest ONL thickness in the peripheral retina of the CNTF-treated eye.

0

None

None

0

/

/

/

/

0

None

None

0

0

None

None

0

Z287

0

None

None

0

0

None

None

0

0

None

None

0

0

None

None

0

Z288

Group 4 (Inj 12; Ter 15.6)
Z286

L: length of retina (measured in μm from the ora serrata) over which there is an increase in ONL thickness in the CNTF-treated eye in comparison to the PBS-treated eye.

SUP: superior meridian; INF: Inferior meridian; NAS: Nasal meridian; TEMP: Temporal meridian; ONL: outer nuclear layer; IS: inner segment; OS: outer segment.

TEMP

NAS

INF

SUP

Table 3

Increase in ONL thickness and loss of IS and OS in the XLPRA2 peripheral retina after CNTF treatment.
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Table 4

ONL nuclear count (mean [min; max]) in a 40X microscope field (290 μm in length) of the peripheral XLPRA2 retina
treated with CNTF or PBS. (Note: rod-like nuclei present in the INL were also included in this count)
Dog:meridian

Z265:

PBS-injected

CNTF-injected

(Inj. 4 wk; Ter. 8 wk)

(Inj. 4 wk; Ter. 8 wk)

% increase

Superior

483 [469; 498]

552 [546; 556]

14

Inferior

362 [360; 366]

544 [533; 553]

50

398 [391; 406]

530 [520; 548]

33

(Inj. 4 & 8 wk; Ter. 12 wk)

(Inj. 4 & 8 wk; Ter. 12 wk)

Temporal
Z261:
Superior

363 [341; 384]

424 [411; 431]

17

Inferior

298 [280; 318]

421 [400; 445]

41

Temporal

321 [313; 331]

393 [376; 416]

22
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Table 5

Number of BrdU-positive cells per unit length of retina (10,000 μm) following CNTF or PBS injection in a 5week-old
XLPRA2 dog. Mean [minimum; maximum] values were obtained from at least three sections for each of the meridians.
Meridian PBS-injected CNTF-injected
Superior

43 [39; 47]

138 [122; 161]

Inferior

54 [41; 65]

101 [97; 104]

Temporal

45 [34; 55]

165 [140; 187]
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